MiMedx Group (MDXG) Given Daily Media Impact Rating of 0.27
News stories about MiMedx Group (NASDAQ:MDXG) have trended positive recently, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. MiMedx Group earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 46.7806464404627 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- MiMedx : Reiterates Its Third Quarter Revenue Expectation To Exceed $80 Million Despite Hurricane Irma (4-traders.com)
- MiMedx Group, Inc. (MDXG)- Analysts Detailing with Profitability Ratio Analysis – NASDAQ Times (nasdaqtimes.com)
- MiMedx Backs Q3 Revenue View Despite Hurricane Irma Impact (nasdaq.com)
- MiMedx Group (MDXG) See Q3 Revenue Over $80M Despite Hurricane Irma (streetinsider.com)
- MiMedx Reiterates Its Third Quarter Revenue Expectation To Exceed $80 Million Despite Hurricane Irma (finance.yahoo.com)
A number of analysts recently weighed in on MDXG shares. First Analysis cut shares of MiMedx Group from an “equal weight” rating to an “underweight” rating and set a $11.00 target price for the company. in a report on Tuesday, May 23rd. BidaskClub upgraded shares of MiMedx Group from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $20.00 price objective (up previously from $15.00) on shares of MiMedx Group in a research note on Monday, June 26th. Lake Street Capital raised their price objective on shares of MiMedx Group from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $18.00 price objective on shares of MiMedx Group in a research note on Sunday, August 20th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $14.83.
MiMedx Group (NASDAQ MDXG) traded down 0.37% on Friday, hitting $13.56. 4,735,014 shares of the stock were exchanged. MiMedx Group has a one year low of $7.64 and a one year high of $17.47. The company has a 50 day moving average of $15.47 and a 200 day moving average of $13.30. The stock has a market capitalization of $1.53 billion, a P/E ratio of 71.37 and a beta of 0.98.
MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, July 26th. The medical equipment provider reported $0.07 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.07. MiMedx Group had a net margin of 7.48% and a return on equity of 15.95%. The business had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $74.22 million. During the same quarter in the prior year, the company posted $0.05 earnings per share. The firm’s revenue was up 33.3% on a year-over-year basis. On average, equities research analysts forecast that MiMedx Group will post $0.31 earnings per share for the current fiscal year.
MiMedx Group announced that its board has initiated a stock buyback program on Wednesday, July 26th that permits the company to buyback $14.00 million in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 0.9% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its stock is undervalued.
MiMedx Group Company Profile
MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
Receive News & Stock Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related stocks with our FREE daily email newsletter.